It is a single research vial combining two growth hormone secretagogues: 5 mg of CJC-1295 without DAC (Modified GRF 1-29), a short-acting analog of growth hormone-releasing hormone (GHRH), and 5 mg of Ipamorelin, a selective growth hormone-releasing peptide (GHRP) that mimics ghrelin. It is supplied as a lyophilized powder for laboratory research use only.

CJC-1295 (no DAC / Mod GRF 1-29) is a 29-residue chain: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2. Ipamorelin is a pentapeptide: Aib-His-D-2-Nal-D-Phe-Lys-NH2.

They act on two different pituitary receptors. CJC-1295 (no DAC) agonizes the GHRH receptor to raise the amplitude of GH pulses, while ipamorelin activates the ghrelin/GHS-R1a receptor to initiate a pulse and dampen somatostatin tone. In research models the two pathways act synergistically, producing greater GH release than either alone.

DAC stands for Drug Affinity Complex, an albumin-binding moiety that extends the analog's half-life to several days. The 'no DAC' form (Mod GRF 1-29) lacks this moiety and is short-acting, with a plasma half-life on the order of ~30 minutes, giving a more pulsatile profile in research.

The two components differ. CJC-1295 without DAC is short-acting at roughly 30 minutes, while ipamorelin has a terminal half-life of about 2 hours measured in healthy human volunteers (Gobburu et al., Pharmaceutical Research, 1999).

No. It is sold strictly for in-vitro and non-human laboratory research. It is not a medicine, supplement, or cosmetic, is not for human or veterinary use, and is not for consumption.

It is a single research vial combining two growth hormone secretagogues: 5 mg of CJC-1295 without DAC (Modified GRF 1-29), a short-acting analog of growth hormone-releasing hormone (GHRH), and 5 mg of Ipamorelin, a selective growth hormone-releasing peptide (GHRP) that mimics ghrelin. It is supplied as a lyophilized powder for laboratory research use only.

CJC-1295 (no DAC / Mod GRF 1-29) is a 29-residue chain: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2. Ipamorelin is a pentapeptide: Aib-His-D-2-Nal-D-Phe-Lys-NH2.

They act on two different pituitary receptors. CJC-1295 (no DAC) agonizes the GHRH receptor to raise the amplitude of GH pulses, while ipamorelin activates the ghrelin/GHS-R1a receptor to initiate a pulse and dampen somatostatin tone. In research models the two pathways act synergistically, producing greater GH release than either alone.

DAC stands for Drug Affinity Complex, an albumin-binding moiety that extends the analog's half-life to several days. The 'no DAC' form (Mod GRF 1-29) lacks this moiety and is short-acting, with a plasma half-life on the order of ~30 minutes, giving a more pulsatile profile in research.

The two components differ. CJC-1295 without DAC is short-acting at roughly 30 minutes, while ipamorelin has a terminal half-life of about 2 hours measured in healthy human volunteers (Gobburu et al., Pharmaceutical Research, 1999).

No. It is sold strictly for in-vitro and non-human laboratory research. It is not a medicine, supplement, or cosmetic, is not for human or veterinary use, and is not for consumption.